{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-044096","form_type":"8-K","ticker":"AXSM","cik":"0001579428","company_name":"Axsome Therapeutics, Inc.","filed_at":"2025-03-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.060026+00:00","generated_at":"2026-05-24T05:47:37.728836+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Axsome solriamfetol Phase 3 ADHD trial meets primary endpoint (p=0.039)","bullets":["AISRS total score reduced 17.7 pts vs 14.3 for placebo at Week 6 (p=0.039) with 150 mg dose.","Key secondary endpoint CGI-S severity score also significant (p=0.017) for 150 mg solriamfetol.","53.5% of 150 mg patients achieved clinical response (≥30% AISRS reduction) vs 41.3% placebo (p=0.024).","Onset of improvement observed as early as Week 1 (p=0.036) vs placebo.","Company plans to initiate pediatric ADHD trial in 2025; safety profile consistent with prior studies."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-044096","json":"https://secwatch.observer/filing/0000950170-25-044096.json","markdown":"https://secwatch.observer/filing/0000950170-25-044096.md","text":"https://secwatch.observer/filing/0000950170-25-044096.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1579428/000095017025044096/0000950170-25-044096-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1579428/000095017025044096/axsm-20250325.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T05:47:37.728836+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}